The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly ...

Patients with bullous pemphigoid experienced symptom improvement with dupilumab treatment, according to a study.“Bullous pemphigoid (BP) is one of the most common autoimmune bullous diseases ...

Key takeaways: Patients with bullous pemphigoid treated with IL-2 had fewer days to disease control vs. those on corticosteroids alone. In the first 2 weeks of IL-2 treatment, a significant ...

References: Dupixent ® (dupilumab) Is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid (BP) positive pivotal trial. News ...

— The interleukin (IL)-4 and IL-13 inhibitor dupilumab improved itch symptoms and curtailed disease activity while also reducing oral corticosteroid use in older patients with bullous pemphigoid ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.. Bullous pemphigoid is a chronic, relapsing skin disease ...

Treatment should make BP more tolerable to each individual patient through the reduction of blister formation, ... Cite this: Bullous Pemphigoid: A Short Review - Medscape - Nov 01, 2009.